Category Leader Forecast: $2.5B → $27B (2027–2032)
Primary investor forecast anchored on GB300+ rack shipments and validated unit economics ($88K BOM + $168K/yr Cryo-Boost licensing). Revenue = new deployment + installed-base recurring.
2027 revenue at 10% GB300+ share — 7,000 racks deployed.
2032 revenue at 25% category leader share — 116,800 cumulative racks.
2032 EBITDA at 65% margin — licensing drives 92%+ gross margin on recurring.
| Year | Market Share | New Racks | Cumulative | Revenue | EBITDA |
|---|---|---|---|---|---|
| 2027 | 10% | 7,000 | 7,000 | $2.5B | $530M |
| 2028 | 12% | 9,600 | 16,600 | $4.7B | $980M |
| 2029 | 15% | 15,000 | 31,600 | $8.4B | $2.1B |
| 2030 | 18% | 21,600 | 53,200 | $13.4B | $3.9B |
| 2031 | 22% | 28,600 | 81,800 | $19.8B | $6.7B |
| 2032 | 25% | 35,000 | 116,800 | $27.3B | $9.2B |